EIF3F and colorectal carcinoma: Next, we established PDX model[27] for testing the drug efficacy of combined treatment on CRC tumor growth in two CRC PDX sets (eIF3f high versus eIF3f low), and the expressing levels of eIf3f were characterized by immunoblotting (Figure 7B).